Novel aspects of postprandial lipemia in relation to atherosclerosis

Atherosclerosis Supplements

Volumn 9, Issue 2, 2008, Pages 39-44

  Alipour, A ^a   Elte, J W F ^a   van Zaanen, H C T ^a   Rietveld, A P ^a   Castro Cabezas, M ^a  

^a SINT FRANCISCUS GASTHUIS   (Netherlands)

Author keywords

Complement; Inflammation; Leukocytes; Triglyceride rich lipoproteins

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ATORVASTATIN; CHYLOMICRON REMNANT; CIPROFIBRATE; COMPLEMENT COMPONENT C3; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MANNOSE BINDING LECTIN; METFORMIN; NICOTINIC ACID; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ALIMENTARY LIPEMIA; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CLINICAL PRACTICE; COMPLEMENT SYSTEM; CORRELATION ANALYSIS; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INNATE IMMUNITY; LEUKOCYTE; LEUKOCYTE ACTIVATION; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NONHUMAN; POSTPRANDIAL STATE; PRIORITY JOURNAL; RISK FACTOR;

ATHEROSCLEROSIS; HUMANS; HYPERLIPIDEMIAS; LEUKOCYTES; LIPOPROTEINS; POSTPRANDIAL PERIOD;

EID: 50449088019     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2008.05.007     Document Type: Article

References (61)

1. Austin M.A., Hokanson J.E., and Edwards K.L. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 81 (1998) 7B-12B
2. Van Oostrom A.J.H.H.M., Castro Cabezas M., Ribalta J., et al. Diurnal triglyceride profiles in healthy normolipidemic male subjects are associated to insulin sensitivity, body composition and diet. Eur J Clin Invest 30 (2000) 964-971
3. Castro Cabezas M., Halkes C.J.M., Meijssen S., van Oostrom A.J.H.H.M., and Erkelens D.W. Diurnal triglyceride profiles: a novel approach to study triglyceride changes. Atherosclerosis 155 (2001) 219-228
4. Van Wijk J.P.H., Halkes C.J.M., Erkelens D.W., and Castro Cabezas M. Fasting and daytime triglycerides in obesity with and without type 2 diabetes. Metabolism 52 (2003) 1043-1049
5. Groot P.H.E., van Stiphout W.A.H.J., Krauss X.H., et al. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arterioscler Thromb 11 (1991) 653-662
6. Halkes C.J., van Dijk H., de Jaegere P.P., et al. Postprandial increase of complement component 3 in normolipidemic patients with coronary artery disease: effects of expanded-dose simvastatin. Arterioscler Thromb Vasc Biol 21 (2001) 1526-1530
7. Van Oostrom A.J.H.H.M., Sijmonsma T.P., Verseyden C., et al. Postprandial recruitment of neutrophils may contribute to endothelial dysfunction. J Lipid Res 44 (2003) 576-583
8. Norata G.D., Grigore L., Raselli S., et al. Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies. Atherosclerosis 193 (2007) 321-327
9. Alipour A., Elte J.W.F., Rietveld A.P., van Zaanen H.C.T., and Castro Cabezas M. Postprandial inflammation and endothelial dysfunction. Biochem Soc Trans 35 Pt 3 (2007) 466-469
10. Van Oostrom A.J.H.H.M., Plokker H.W.M., van Asbeck B.S., et al. Effects of rosuvastatin on postprandial leukocytes in mildly hyperlipidemic patients with premature coronary sclerosis. Atherosclerosis 185 (2006) 331-339
11. Van Oostrom A.J.H.H.M., Alipour A., Plokker H.W.M., Sniderman A.D., and Castro Cabezas M. The metabolic syndrome in relation to complement component 3 and postprandial lipemia in patients from an outpatient lipid clinic and healthy volunteers. Atherosclerosis 190 (2007) 167-173
12. Castro Cabezas M., de Bruin T.W.A., Kock L.A.W., and de Bruin T.W. Postprandial apolipoprotein B100 and apo B48 in familial combined hyperlipidemia before and after reduction of fasting plasma triglycerides. Eur J Clin Invest 24 (1994) 669-678
13. Karpe F., Tornvall P., Olivecrona T., et al. Composition of human low density lipoprotein: effects of postprandial triglyceride-rich lipoproteins, lipoprotein lipase, hepatic lipase and cholesteryl ester transfer protein. Atherosclerosis 98 (1993) 33-49
14. Zilversmit D.B. Atherogenesis: a postprandial phenomenon. Circulation 60 (1979) 473-485
15. Karpe F., Steiner G., Uffelman K., Olivecrona T., and Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 106 (1994) 83-97
16. Ceriello A., Taboga C., Tonutti L., et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short-and long-term simvastatin treatment. Circulation 106 (2002) 1211-1218
17. Bravo E., and Napolitano M. Mechanisms involved in chylomicron remnant lipid uptake by macrophages. Biochem Soc Trans 35 Pt 3 (2007) 459-463
18. Delawi D., Meijssen S., and Castro Cabezas M. Intra-individual variations of fasting plasma lipids, apolipoproteins and postprandial lipemia in familial combined hyperlipidemia compared to controls. Clin Chim Acta 328 (2003) 139-145
19. Stampfer M.J., Krauss R.M., Ma J., et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 276 (1996) 882-888
20. Bansal S., Buring J.E., Rifai N., et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 298 (2007) 309-316
21. Nordestgaard B.G., Benn M., Schnohr P., and Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298 (2007) 299-308
22. Castro Cabezas M., de Bruin T.W., Jansen H., et al. Impaired chylomicron remnant clearance in familial combined hyperlipidemia. Arterioscler Thromb 13 (1993) 804-814
23. Patsch J.R., Miesenböck G., and Patsch W. Relation of triglyceride metabolism and coronary disease. Studies in the postprandial state. Arterioscler Thromb 12 (1992) 1336-1345
24. Halkes C.J.M., Castro Cabezas M., van Wijk J.P.H., and Erkelens D.W. Gender differences in diurnal triglyceridemia in lean and overweight subjects. Int J Obes 25 (2001) 1767-1774
25. Matikainen N., Mänttäri S., Westerbacka J., et al. Postprandial lipemia associates with liver fat content. J Clin Endocrinol Metab 92 (2007) 3052-3059
26. Van Wijk J.P.H., Castro Cabezas M., Halkes C.J.M., and Erkelens D.W. Effects of different nutrient intakes on daytime triacylglycerolemia in healthy, normolipemic, free-living men. Am J Clin Nutr 74 (2001) 171-178
27. Walport M.J. Complement; first of two parts. N Engl J Med 344 (2001) 1058-1065
28. Cianflone K., Xia Z., and Chen L.Y. Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim Biophys Acta 1609 (2003) 127-143
29. Van Oostrom A.J., van Wijk J., and Castro Cabezas M. Lipaemia, inflammation and atherosclerosis: novel opportunities in the understanding and treatment of atherosclerosis. Drugs 64 Suppl. 2 (2004) 19-41
30. Strunk R.C., Kunke K.S., and Giclas P.C. Human peripheral blood monocyte-derived macrophages produce haemolytically active C3 in vitro. Immunology 49 (1983) 169-174
31. Vaisar T., Pennathur S., Green P.S., et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 117 (2007) 746-756
32. Alipour A., van Oostrom A.J.H.H.M., Van Wijk J.P.H., et al. Deficiency of mannose binding lectin is associated to impaired metabolism of VLDL1 particles despite fasting plasma triglycerides. Circulation Suppl. (2007) 1098
33. Best L.G., Davidson M., North K.E., et al. Prospective analysis of mannose-binding lectin genotypes and coronary artery disease in American Indians. Circulation 109 (2004) 471-475
34. Madsen H.O., Videm V., Svejgaard A., Svennevig J.L., and Garred P. Association of mannose-binding lectin deficiency with severe atherosclerosis. Lancet 352 (1998) 959-960
35. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
36. Tertov V.V., Kalenich O.S., and Orekhov A.N. Lipid-laden white blood cells in the circulation of patients with coronary heart disease. Exp Mol Pathol 57 (1992) 22-28
37. Alipour A., van Oostrom A.J.H.H.M., Izraeljan A., et al. Leukocyte activation by triglyceride-rich lipoproteins. Arterioscler Thromb Vasc Biol 28 (2008) 792-797 [Epub ahead of print]
38. Verseyden C., Meijssen S., and Castro Cabezas M. Effects of atorvastatin on fasting plasma and marginated apolipoproteins B48 and B100 in large, triglyceride-rich lipoproteins in familial combined hyperlipidemia. J Clin Endocrinol Metab 89 (2004) 5021-5029
39. Cohn J.S. Postprandial lipemia and remnant lipoproteins. Clin Lab Med 26 (2006) 773-786
40. Bruun J.M., Verdich C., Toubro S., Astrup A., and Richelsen B. Association between measures of insulin sensitivity and circulating levels of interleukin-8, interleukin-6 and tumor necrosis factor-alpha. Effect of weight loss in obese men. Eur J Endocrinol 148 (2003) 535-542
41. Karason K., Wikstrand J., Sjostrom L., and Wendelhag I. Weight loss and progression of early atherosclerosis in the carotid artery: a four-year controlled study of obese subjects. Int J Obes Relat Metab Disord 23 (1999) 948-956
42. Riches F.M., Watts G.F., Hua J., et al. Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men. J Clin Endocrinol Metab 84 (1999) 2854-2861
43. Fruchart J.C., Brewer H.B., and Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Am J Cardiol 81 (1998) 912-917
44. Evans M., Anderson R.A., Graham J., et al. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation 101 (2000) 1773-1779
45. Ooi T.C., Cousins M., Ooi D.S., Nakajima K., and Edwards A.L. Effect of fibrates on postprandial remnant-like particles in patients with combined hyperlipidemia. Atherosclerosis 172 (2004) 375-382
46. Syvänne M., Nieminen M.S., Frick H., et al. Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol. Circulation 98 (1998) 1993-1999
47. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341 (1999) 410-418
48. Ericsson C.G., Hamsten A., Nilsson J., et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347 (1996) 849-853
49. Ruotolo G., Ericsson C.-G., Tettamanti C., et al. Treatment effect on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the bezafibrate coronary atherosclerosis intervention trial (BECAIT). J Am Coll Cardiol 32 (1998) 1648-1656
50. Keech A., Simes R.J., Barter P., et al. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
51. King J.M., Crouse J.R., Terry J.G., et al. Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia. Am J Med 97 (1994) 323-331
52. Grosskopf I., Ringel Y., Charach G., et al. Metformin enhances clearance of chylomicrons and chylomicron remnants in nondiabetic mildly overweight glucose-intolerant subjects. Diabetes Care 20 (1997) 1598-1602
53. van Wijk J.P.H., de Koning E.J.P., Castro Cabezas M., and Rabelink T.J. Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes. Diabetes Care 28 (2005) 844-879
54. Dormandy J.A., Charobonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
55. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
56. Singh S., Loke Y.K., and Furberg C.D. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298 (2007) 1189-1195
57. Ginsberg H.N. Effects of statins on triglyceride metabolism. Am J Cardiol 81 4A (1998) 32B-35B
58. Castro Cabezas M., Verseyden C., Jansen H., and Meijssen S. Effects of atorvastatin on the clearance of triglyceride rich lipoproteins in familial combined hyperlipidemia. J Clin Endocrinol Metab 89 (2004) 5972-5980
59. Jones P., Kafonek S., Laurora I., and Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the curves study). Am J Cardiol 81 (1998) 582-587
60. Pitt B., Waters D., Brown W.V., et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 341 (1999) 70-76
61. Dupuis J., Tardif J.C., Cernacek P., and Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) trial. Circulation 99 (1999) 3227-3233